Jianmin Pharmaceutical GroupLtd Past Earnings Performance
Past criteria checks 4/6
Jianmin Pharmaceutical GroupLtd has been growing earnings at an average annual rate of 37.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 15.1% per year. Jianmin Pharmaceutical GroupLtd's return on equity is 22.2%, and it has net margins of 12.5%.
Key information
37.8%
Earnings growth rate
37.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 15.1% |
| Return on equity | 22.2% |
| Net Margin | 12.5% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Jianmin Pharmaceutical GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 4,170 | 521 | 1,441 | 79 |
| 31 Dec 23 | 4,213 | 521 | 1,518 | 74 |
| 30 Sep 23 | 3,948 | 508 | 1,425 | 78 |
| 30 Jun 23 | 3,965 | 472 | 1,409 | 78 |
| 31 Mar 23 | 3,736 | 419 | 1,311 | 74 |
| 31 Dec 22 | 3,641 | 408 | 1,214 | 73 |
| 30 Sep 22 | 3,503 | 363 | 1,192 | 74 |
| 30 Jun 22 | 3,344 | 326 | 1,126 | 67 |
| 31 Mar 22 | 3,376 | 324 | 1,125 | 62 |
| 31 Dec 21 | 3,299 | 305 | 1,134 | 53 |
| 30 Sep 21 | 3,456 | 279 | 1,135 | 39 |
| 30 Jun 21 | 3,221 | 258 | 1,083 | 38 |
| 31 Mar 21 | 2,857 | 199 | 1,056 | 41 |
| 01 Jan 21 | 2,456 | 148 | 891 | 37 |
| 30 Sep 20 | 2,013 | 144 | 812 | 45 |
| 30 Jun 20 | 2,154 | 93 | 801 | 42 |
| 31 Mar 20 | 2,164 | 83 | 780 | 36 |
| 01 Jan 20 | 2,239 | 91 | 791 | 41 |
| 30 Sep 19 | 2,402 | 82 | 745 | 28 |
| 30 Jun 19 | 2,199 | 80 | 696 | 30 |
| 31 Mar 19 | 2,183 | 79 | 668 | 29 |
| 01 Jan 19 | 2,161 | 81 | 671 | 26 |
| 30 Sep 18 | 2,188 | 91 | 740 | 27 |
| 30 Jun 18 | 2,311 | 100 | 721 | 35 |
| 31 Mar 18 | 2,625 | 102 | 683 | 30 |
| 31 Dec 17 | 2,712 | 91 | 647 | 24 |
| 30 Sep 17 | 2,748 | 81 | 604 | 15 |
| 30 Jun 17 | 2,677 | 71 | 579 | 0 |
| 31 Mar 17 | 2,315 | 59 | 543 | 0 |
| 31 Dec 16 | 2,364 | 65 | 509 | 0 |
| 30 Sep 16 | 2,495 | 69 | 456 | 0 |
| 30 Jun 16 | 2,430 | 80 | 448 | 0 |
| 31 Mar 16 | 2,449 | 83 | 424 | 0 |
| 31 Dec 15 | 2,281 | 86 | 404 | 0 |
| 30 Sep 15 | 1,953 | 86 | 384 | 0 |
| 30 Jun 15 | 1,860 | 102 | 324 | 0 |
| 31 Mar 15 | 1,748 | 114 | 317 | 0 |
| 31 Dec 14 | 1,753 | 116 | 328 | 0 |
| 30 Sep 14 | 1,685 | 118 | 314 | 0 |
| 30 Jun 14 | 1,716 | 108 | 332 | 0 |
| 31 Mar 14 | 1,867 | 98 | 339 | 0 |
| 31 Dec 13 | 1,992 | 96 | 336 | 0 |
| 30 Sep 13 | 1,945 | 99 | 324 | 0 |
| 30 Jun 13 | 1,880 | 92 | 312 | 0 |
Quality Earnings: 600976 has a high level of non-cash earnings.
Growing Profit Margin: 600976's current net profit margins (12.5%) are higher than last year (11.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600976's earnings have grown significantly by 37.8% per year over the past 5 years.
Accelerating Growth: 600976's earnings growth over the past year (24.5%) is below its 5-year average (37.8% per year).
Earnings vs Industry: 600976 earnings growth over the past year (24.5%) exceeded the Pharmaceuticals industry -1.6%.
Return on Equity
High ROE: 600976's Return on Equity (22.2%) is considered high.